
邮箱:shimeng.xu@ncu.edu.cn
地址:前湖校区南院科创楼427
研究方向:脂代谢及相关疾病药物靶点确证和药物开发
个人主页:https://teacher.ncu.edu.cn/publish/093521/
教育经历
2006.9-2010.7 贵州大学,生物科学,学士
2010.9-2016.6 中国科学院生物物理研究所,细胞生物学,博士
工作履历
2016.7-2018.1 中国科学院生物物理研究所,博士后
2018.1-2022.6 美国德州西南医学中心,博士后
2022.7-2025.4 美国德州西南医学中心, Senior Research Scientist
2025.4-至今 南昌大学生物医学创新研究院/基础医学院,特聘研究员
主要从事胆固醇代谢调控与脂滴生物学研究。近年来围绕SCAP/SREBP代谢通路,构建了“发现新通路-探索生理病理功能-筛选小分子-开发靶向治疗”的研究体系,相关成果以第一及共同通讯作者发表在PNAS (2020,2024), Science Bulletins (2021), JLR (2024), BBA-Mol Biol (2021)等国际知名学术期刊上。
研究方向:
1) 胆固醇合成及代谢新通路的发现和机制研究;
2) 胆固醇合成及代谢调控小分子的筛选及作用靶点确证;
3) E3泛素链接酶MARCH6在调控脂代谢及相关肝脏疾病中的作用机制。
(1) Shimeng Xu*; Jared C. Smothers; Daphne Rye; Shreya Endapally; Hong Chen; Shili Li; Guosheng Liang; Maia Kinnebrew; Rajat Rohatgi; Bruce A. Posner; Arun Radhakrishnan; A cholesterol-binding bacterial toxin provides a strategy for identifying a specific Scap inhibitor that blocks lipid synthesis in animal cells, PNAS, 2024, 121(7)
(2) Shimeng Xu*; Linda Donnelly; Daniel L. Kober; Myra Mak; Arun Radhakrishnan; Development of a monoclonal antibody to study MARCH6, an E3 ligase that regulates proteins that control lipid homeostasis, Journal of Lipid Research, 2024, 65(11): 100650
(3) Daniel L. Kober*; Shimeng Xu*; Shili Li; Bilkish Bajaj; Guosheng Liang; Daniel M. Rosenbaum; Arun Radhakrishnan ; Identification of a degradation signal at the carboxy terminus of SREBP2: A new role for this domain in cholesterol homeostasis, PNAS, 2020, 11
(4) Yaqin Deng; Chang Zhou; Ahmed Hammad Mirza; Adekunle Toyin Bamigbade; Shuyan Zhang; Shimeng Xu#; Pingsheng Liu#; Rab18 binds PLIN2 and ACSL3 to mediate lipid droplet dynamics, BBA- Mol Biol, 2021, 1866(7)
(5) Ting Huang*; Adekunle T. Bamigbade*; Shimeng Xu*; Yaqin Deng; Kang Xie; Ololade O. Ogunsade; Ahmed Hammad Mirza; Jifeng Wang; Pingsheng Liu; Shuyan Zhang ; Identification of noncoding RNAencoded proteins on lipid droplets, Science Bulletin, 2021, 66(4): 314-318